Clinical Trial: Efficacy of Sivelestat in Treating Sepsis Patients with ARDS and SCM
Background
Researchers assessed the effectiveness of sivelestat, a neutrophil elastase inhibitor, in treating sepsis-induced acute respiratory distress syndrome (ARDS) and septic cardiomyopathy (SCM).
Methods
A randomized trial was conducted on patients diagnosed with sepsis-induced ARDS and SCM at Wuhan Union Hospital. The patients were divided into Sivelestat and Control groups. Serum concentrations of certain inflammatory markers were measured at five time points from baseline to 72 hours after admission to the ICU. Cardiac function was also evaluated using sonography and heart rate variability monitoring.
Results
The study included 70 patients, and the Sivelestat group showed significantly lower levels of inflammatory markers at different time points. Additionally, improvements in cardiac function were observed in the Sivelestat group compared to the Control group.
Conclusions
Sivelestat treatment significantly reduced serum inflammatory factors, improved cardiac function, and reduced heart rate variability in patients with sepsis-induced ARDS and SCM.
Value of Clinical Trials in Healthcare
Clinical trials are essential for developing safe and effective treatments, and our AI-driven platform, DocSym, consolidates clinical knowledge and protocols for clinicians’ accessibility.
Practical Solutions for Healthcare Operations
Streamlining healthcare operations is crucial in today’s environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, providing digital expansion of services and efficient patient care management.
Utilizing AI, clinics can improve workflows, enhance patient outcomes, and reduce paper-based routines. Learn more at aidevmd.com.
